SG11202102478SA - Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor - Google Patents

Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Info

Publication number: SG11202102478SA
Authority: SG; Singapore
Prior art keywords: pai; inhibitors; plasminogen activator; activator inhibitor; uses therefor
Prior art date: 2018-09-13

Eirion Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-09-12Application filed by Eirion Therapeutics IncfiledCriticalEirion Therapeutics Inc

2021-04-29Publication of SG11202102478SApublicationCriticalpatent/SG11202102478SA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

SG11202102478SA2018-09-132019-09-12Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses thereforSG11202102478SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862731074P	2018-09-13	2018-09-13
PCT/US2019/050849WO2020056160A1 (en)	2018-09-13	2019-09-12	Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Publications (1)

Publication Number	Publication Date
SG11202102478SAtrue SG11202102478SA (en)	2021-04-29

Family

ID=68052024

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202102478SASG11202102478SA (en)	2018-09-13	2019-09-12	Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Country Status (12)

Country	Link
US (1)	US20220105068A1 (en)
EP (1)	EP3849539A1 (en)
JP (2)	JP2021535925A (en)
KR (1)	KR20210057141A (en)
CN (1)	CN113056268A (en)
AU (1)	AU2019338459A1 (en)
BR (1)	BR112021004542A2 (en)
CA (1)	CA3112558A1 (en)
IL (1)	IL281450A (en)
MX (1)	MX2021002995A (en)
SG (1)	SG11202102478SA (en)
WO (1)	WO2020056160A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2019535829A (en)	2016-11-21	2019-12-12	エイリオンセラピューティクス，インコーポレイテッド	Transdermal delivery of large drugs
CN113155987B (en)*	2020-12-28	2023-06-06	浙江工商大学	A kind of microneedle patch and its preparation method and application
WO2025064449A1 (en)	2023-09-18	2025-03-27	Eirion Therapeutics, Inc.	Topical compositions and uses of pai-1 inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US296006A (en)		1884-04-01		John hoefleb
US4270537A (en)	1979-11-19	1981-06-02	Romaine Richard A	Automatic hypodermic syringe
US4886499A (en)	1986-12-18	1989-12-12	Hoffmann-La Roche Inc.	Portable injection appliance
GB8704027D0 (en)	1987-02-20	1987-03-25	Owen Mumford Ltd	Syringe needle combination
FR2638359A1 (en)	1988-11-03	1990-05-04	Tino Dalto	SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5008110A (en)	1988-11-10	1991-04-16	The Procter & Gamble Company	Storage-stable transdermal patch
US5190521A (en)	1990-08-22	1993-03-02	Tecnol Medical Products, Inc.	Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en)	1990-12-13	1996-06-18	Elan Medical Technologies Limited	Intradermal drug delivery device and method for intradermal delivery of drugs
SE9102652D0 (en)	1991-09-13	1991-09-13	Kabi Pharmacia Ab	INJECTION NEEDLE ARRANGEMENT
US5328483A (en)	1992-02-27	1994-07-12	Jacoby Richard M	Intradermal injection device with medication and needle guard
US6010715A (en)	1992-04-01	2000-01-04	Bertek, Inc.	Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (en)	1993-09-02	1996-06-03	Avantgarde Spa	MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR VERY LOW DOSAGE DRUGS, IN PARTICULAR HOMEOPATHIC DRUGS.
US5948433A (en)	1997-08-21	1999-09-07	Bertek, Inc.	Transdermal patch
IT1298087B1 (en)	1998-01-08	1999-12-20	Fiderm S R L	DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
US5965154A (en)	1998-03-17	1999-10-12	Plc Holding, L.L.C.	Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en)	1998-06-10	2003-01-07	Georgia Tech Research Corporation	Microneedle device for transport of molecules across tissue
US6611707B1 (en)	1999-06-04	2003-08-26	Georgia Tech Research Corporation	Microneedle drug delivery device
WO2001051085A1 (en)*	2000-01-14	2001-07-19	Tanox, Inc.	Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
US6908453B2 (en)	2002-01-15	2005-06-21	3M Innovative Properties Company	Microneedle devices and methods of manufacture
EP1485709A4 (en)*	2002-02-19	2005-09-21	Univ Vanderbilt	THERAPY PROCEDURE WITH PAI-1 INHIBITORS AND TRANSGENIC NON-MENTAL ANIMAL FOR SCREENING PAI-1 INHIBITOR CANDIDATES
WO2004041155A2 (en)*	2002-05-13	2004-05-21	Children's Hospital Los Angeles	Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
CA2578529A1 (en)*	2004-08-18	2006-02-23	Ace Aps	Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
AU2006349377B2 (en)	2005-12-01	2013-06-27	University Of Massachusetts Lowell	Botulinum nanoemulsions
EP2015773A4 (en)	2006-04-27	2010-05-05	Anterios Inc	Assessment of the effects of topical administration of chemodenervating pharmaceuticals
AU2007329579A1 (en)	2006-12-01	2008-06-12	Anterios, Inc.	Amphiphilic entity nanoparticles
US8415479B2 (en)*	2008-03-31	2013-04-09	Renascience Co., Ltd.	Inhibitor of plasminogen activator inhibitor-1
MX2010013562A (en)	2008-06-26	2011-02-15	Anterios Inc	DERMIC APPLICATION
KR101563362B1 (en)*	2009-06-26	2015-10-26	써니 팜테크, 인코포레이티드	Pharmaceutical composition for treating or ameliorating toxicities or side effects induced by molecular targeted therapy
AU2012209274A1 (en)	2011-01-24	2013-09-12	Anterios, Inc.	Nanoparticle compositions, formulations thereof, and uses therefor
EP3572072A1 (en)	2011-01-24	2019-11-27	Anterios, Inc.	Nanoparticle compositions
EP2793869B1 (en)	2011-12-21	2015-09-23	3M Innovative Properties Company	Transdermal adhesive patch assembly with removable microneedle array and method of using same

2019
- 2019-09-12KRKR1020217010851Apatent/KR20210057141A/enactivePending
- 2019-09-12BRBR112021004542-2Apatent/BR112021004542A2/enunknown
- 2019-09-12CNCN201980074633.8Apatent/CN113056268A/enactivePending
- 2019-09-12MXMX2021002995Apatent/MX2021002995A/enunknown
- 2019-09-12JPJP2021514401Apatent/JP2021535925A/enactivePending
- 2019-09-12AUAU2019338459Apatent/AU2019338459A1/enactivePending
- 2019-09-12CACA3112558Apatent/CA3112558A1/enactivePending
- 2019-09-12EPEP19773718.2Apatent/EP3849539A1/enactivePending
- 2019-09-12SGSG11202102478SApatent/SG11202102478SA/enunknown
- 2019-09-12WOPCT/US2019/050849patent/WO2020056160A1/enunknown
- 2019-09-12USUS17/274,948patent/US20220105068A1/enactivePending
2021
- 2021-03-11ILIL281450Apatent/IL281450A/enunknown
2024
- 2024-09-12JPJP2024158484Apatent/JP2025011085A/enactivePending

Also Published As

Publication number	Publication date
BR112021004542A2 (en)	2021-06-08
JP2025011085A (en)	2025-01-23
AU2019338459A1 (en)	2021-04-08
KR20210057141A (en)	2021-05-20
JP2021535925A (en)	2021-12-23
IL281450A (en)	2021-04-29
CA3112558A1 (en)	2020-03-19
CN113056268A (en)	2021-06-29
EP3849539A1 (en)	2021-07-21
WO2020056160A1 (en)	2020-03-19
US20220105068A1 (en)	2022-04-07
MX2021002995A (en)	2021-07-15

Publication	Publication Date	Title
IL288381A (en)	2022-01-01	Tead inhibitors and uses thereof
IL288384A (en)	2022-01-01	Tead inhibitors and uses thereof
PL4031547T3 (en)	2024-10-07	Plasma kallikrein inhibitors and uses thereof
SG11202104017VA (en)	2021-05-28	Tyk2 inhibitors and uses thereof
IL286248A (en)	2021-10-31	Tyk2 inhibitors and uses thereof
IL283409A (en)	2021-07-29	Tyk2 inhibitors and uses thereof
IL282090A (en)	2021-05-31	Tyk2 inhibitors and uses thereof
IL284799A (en)	2021-08-31	Tyk2 inhibitors and uses thereof
IL307187A (en)	2023-11-01	Mk2 inhibitors and uses thereof
IL281450A (en)	2021-04-29	Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
ZA202209891B (en)	2023-05-31	Bcl-2 inhibitor
IL282350A (en)	2021-05-31	Rgmc-selective inhibitors and use thereof
IL281451A (en)	2021-04-29	Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
IL279276A (en)	2021-01-31	Erk inhibitor and use thereof
IL291217A (en)	2022-05-01	Usp30 inhibitors and uses thereof
IL285595A (en)	2021-09-30	Spt5 inhibitors and uses thereof
IL276324A (en)	2020-09-30	4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19)
ZA202109737B (en)	2022-07-27	Compound used as kinase inhibitor and application thereof
IL283706A (en)	2021-07-29	Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
PL3657946T3 (en)	2025-03-31	Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use
IL310209A (en)	2024-03-01	Rock2 inhibitors and uses thereof
HK40059344A (en)	2022-05-06	Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
HK40058373A (en)	2022-04-22	Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
HK40025611B (en)	2024-10-25	Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use
GB201908884D0 (en)	2019-08-07	Inhibitors and use

Movatterモバイル変換

SG11202102478SA - Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=68052024

Family Applications (1)

Country Status (12)

Families Citing this family (3)

Family Cites Families (32)

Also Published As

Similar Documents